Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of HS-10504 versus platinum doublet chemotherapy in advanced EGFR-mutant NSCLC with EGFR C797S after EGFR TKI failure
CTR20263038Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HS-10504 in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Aug 2026; status: active.
02
Drugs
HS-10504
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263038.